LabCorp Announces $500 Million Stock Repurchase Program

    BURLINGTON, N.C., March 13 /CNW/ -- Laboratory Corporation of America(R)
Holdings (LabCorp(R)) (NYSE:   LH) today announced that its Board of Directors
has authorized a new stock repurchase program under which LabCorp may purchase
up to an aggregate of $500,000,000 of its Common Stock from time-to-time.
    The purpose of LabCorp's stock repurchase program is consistent with its
goal of making investments of the Company's cash resources that enhance
shareholder value.
    Any purchases under LabCorp's stock repurchase program may be made from
time-to-time in the open market or in privately negotiated transactions and
may be initiated and discontinued at any time.

    About LabCorp

    Laboratory Corporation of America(R) Holdings, a S&P 500 company, is a
pioneer in commercializing new diagnostic technologies and the first in its
industry to embrace genomic testing.  With annual revenues of $3.6 billion in
2006, over 25,000 employees nationwide, and more than 220,000 clients, LabCorp
offers clinical assays ranging from routine blood analyses to HIV and genomic
testing. LabCorp combines its expertise in innovative clinical testing
technology with its Centers of Excellence: The Center for Molecular Biology
and Pathology, in Research Triangle Park, NC; National Genetics Institute,
Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN;
The Center for Esoteric Testing in Burlington, NC; DIANON Systems, Inc. based
in Stratford, CT; US LABS based in Irvine, CA; and Esoterix and its Colorado
Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. 
LabCorp clients include physicians, government agencies, managed care
organizations, hospitals, clinical labs, and pharmaceutical companies. To
learn more about our growing organization, visit our Web site at:

    Each of the above forward-looking statements is subject to change based
on various important factors, including without limitation, competitive
actions in the marketplace and adverse actions of governmental and other
third-party payors.  Actual results could differ materially from those
suggested by these forward-looking statements. Further information on
potential factors that could affect LabCorp's financial results is included in
the Company's Form 10-K for the year ended December 31, 2006, and subsequent
SEC filings.

For further information:

For further information: Investors, Scott Fleming, (336) 436-4879, or
Media, Pam Sherry, (336) 436-4855, both of Laboratory Corporation of America
Holdings, or Shareholder Direct, 1-800-LAB-0401 Web Site:

Organization Profile


More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890